Skip to main content
×
Home
    • Aa
    • Aa

Successes and failures: an overview of lessons learnt in the creation of targeted therapy strategies for breast cancer

  • S. R. D. Johnston (a1)
Abstract
Abstract

Therapies that target cancers according to their characteristics (estrogen receptor +ve or –ve, for example) have been a major development in treating cancers successfully and have led to an increase in survival rates. These successes have led to increased research into even more tightly focused therapies. But targeted therapies do not work for everyone, raising issues of (1) identifying patients and (2) developing therapies that reflect our increasing understanding of the complex and differentiated traits of tumors. New targeted therapies such as small molecule signal transduction inhibitors and monoclonal antibodies are being developed to address tumors at all stages of the cell proliferation cycle and it is hoped that they may eventually transform cancer into a fully treatable condition.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Successes and failures: an overview of lessons learnt in the creation of targeted therapy strategies for breast cancer
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Successes and failures: an overview of lessons learnt in the creation of targeted therapy strategies for breast cancer
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Successes and failures: an overview of lessons learnt in the creation of targeted therapy strategies for breast cancer
      Available formats
      ×
Copyright
Corresponding author
Correspondence to: Dr Stephen R. D. Johnston, MA, FRCP, PhD, Consultant Medical Oncologist, Department of Medicine, Royal Marsden Hospital, Fulham Road, Chelsea, London SW3 6JJ, UK. E-mail: stephen.johnston@rmh.nhs.uk; Tel: +44 207 808 2748; Fax: +44 207 808 2563
References
Hide All
1.Spector NL, Xia W, 3rdBurris H , et al. . Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23: 25022512.
2.Slamon DJ, Leyland-Jones B, Shak S, et al. . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001; 344: 783792.
3.DiLeo A, Gomez H, Aziz Z, et al. . Lapatinib with paclitaxel versus paclitaxel as first-line treatment for patienst with metastatic breast cancer: a phase III randomized, double-blind study in 580 patients. Proc Am Soc Clin Oncol Abs 2007; Abs 1011.
4.Paez JG, Janne PA, Lee JC, et al. . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 14971500.
5.Yu K, Toral-Barza L, Discafani C, et al. . mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249258.
6.Chow LWC, Shun Y, Jassem J, et al. . Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl 1); Abs 6091.
7.Johnston SRD. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in Breast Cancer. Clin Cancer Res 2006; 12: 1061s1068s.
8.Nicholson RI, McClelland RA, Robertson JF, et al. . Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999; 6: 373387.
9.Miller KD, Chap LI, Holmes FA, et al. . Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792799.
10.Geyer CE, Forster J, Lindquist D, et al. . Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355 (26): 27332743.
11.Braun S, Pantel K, Muller P, et al. . Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 525533.
12.Braun S, Kentenich C, Janni W, et al. . Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000; 18: 8086.
13.Bozionellou V, Mavroudis D, Perraki M, et al. . Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 2004; 10: 81858194.
14.Romond EH, Perez EA, Bryant J, et al. . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 16731684.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Breast Cancer Online
  • ISSN: -
  • EISSN: 1470-9031
  • URL: /core/journals/breast-cancer-online
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Full text views

Total number of HTML views: 1
Total number of PDF views: 11 *
Loading metrics...

Abstract views

Total abstract views: 26 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 22nd October 2017. This data will be updated every 24 hours.